Chinese Journal of Tissue Engineering Research ›› 2011, Vol. 15 ›› Issue (14): 2609-2612.doi: 10.3969/j.issn.1673-8225.2011.14.030

Previous Articles     Next Articles

Methylation status in the promoter region of secreted frizzled related protein 5 gene in patients with myelodyplastic syndrome

Shi Xiao-hong1, Fan Yun2, Zhou Chang-hu1, Ning Shang-yong2, Sun Liang1, Zhu Xiao-quan1, Tang Lei1, Chang Nai-bai2, Yang Ze1   

  1. 1Institute of Geriatrics, 2Department of Hematology, Ministry of Public Health, Beijing Hospital, Beijing  100730, China
  • Received:2010-11-23 Revised:2011-01-25 Online:2011-04-02 Published:2013-11-02
  • Contact: Yang Ze, Researcher, Institute of Geriatrics, Ministry of Public Health, Beijing Hospital, Beijing 100730, China yangze016@yahoo.com.cn Correspondence to: Chang Nai-bai, Chief physician, Department of Hematology, Ministry of Public Health, Beijing Hospital, Beijing 100730, China changnaibai@sohu.com
  • About author:Shi Xiao-hong☆, Doctor, Associate investigator, Institute of Geriatrics, Ministry of Public Health, Beijing Hospital, Beijing 100730, China sxh_cnu@yahoo.com.cn Fan Yun, Master, Chief physician, Department of Hematology, Ministry of Public Health, Beijing Hospital, Beijing 100730, China emmafan@sina.com.cn Shi Xiao-hong and Fan Yun contributed equally to this paper.
  • Supported by:

    the Key Foundation of Beijing Hospital, Ministry of Public Health, No. BJ-2008-76*; General Foundation of Beijing Hospita Ministry of Public Health l, No. BJ-2008-110*

PDF

398

Abstract:

BACKGROUND: Methylation in the promoter region of secreted frizzled related protein 5 (SFRP5) gene is closely related to acute myeloid leukemia. As a pre-leukemia, methylation status in the promoter region of SFRP5 gene in patients with myelodyplastic syndrome (MDS) remains unclear.
OBJECTIVE: To investigate the methylation status in the promoter region of SFRP5 gene in patient with MDS.
METHODS: Methylation specific PCR (MSP) method was applied to examine the promoter methylation of SFRP5 gene in 43 bone marrow or peripheral blood samples of MDS patients, and 70 normal peripheral blood samples from volunteers of general outpatients as controls.
RESULTS AND CONCLUSION: All 113 samples were involved for the results analysis. In 43 patients of MDS, 5 samples (11.6%) showed SFRP5 gene methylation. In 70 controls, 1 sample showed SFRP5 gene methylation. And all of them were part-methylation status. The frequency of SFRP5 gene methylation in MDS patients was significantly higher than that in controls (χ2=5.511, P=0.019). Of the 43 MDS patients’ samples, 17 cases were bone marrow samples, 26 cases were peripheral blood samples. Of the 5 SFRP5 gene methylation samples, 2 cases were bone marrow samples and 3 cases were peripheral blood samples. There was no significant difference between the different sample source (bone marrow or peripheral blood ) for the results of the methylation status (χ2=0.001, P=0.982). The methylation status of SFRP5 gene was correlated with MDS. The methylation of SFRP5 gene may be one of the molecular mechanisms that contributes to the prognosis of patients with MDS.

CLC Number: